Literature DB >> 19843848

Nuclear receptor coregulators in cancer biology.

Bert W O'Malley1, Rakesh Kumar.   

Abstract

Coregulators (coactivators and corepressors) occupy the driving seat for actions of all nuclear receptors, and consequently, selective receptor modulator drugs. The potency and selectivity for subreactions of transcription reside in the coactivators, and thus, they are critically important for tissue-selective gene function. Each tissue has a "quantitative finger print" of coactivators based on its relative inherited concentrations of these molecules. When the cellular concentration of a coactivator is altered, genetic dysfunction usually leads to a pathologic outcome. For example, many cancers overexpress "growth coactivators." In this way, the cancer cell can hijack these coactivator molecules to drive proliferation and metastasis. The present review contains summaries of selective coactivators and corepressors that have been demonstrated to play important roles in the malignant process and emphasizes their importance for future therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843848      PMCID: PMC2783444          DOI: 10.1158/0008-5472.CAN-09-2223

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

1.  Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation.

Authors:  Y Zhang; H H Ng; H Erdjument-Bromage; P Tempst; A Bird; D Reinberg
Journal:  Genes Dev       Date:  1999-08-01       Impact factor: 11.361

2.  Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase.

Authors:  H Chen; R J Lin; W Xie; D Wilpitz; R M Evans
Journal:  Cell       Date:  1999-09-03       Impact factor: 41.582

3.  Identification of Pax5 as a target of MTA1 in B-cell lymphomas.

Authors:  Seetharaman Balasenthil; Anupama E Gururaj; Amjad H Talukder; Rozita Bagheri-Yarmand; Ty Arrington; Brian J Haas; John C Braisted; Insun Kim; Norman H Lee; Rakesh Kumar
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 4.  Nuclear receptor coregulators and human disease.

Authors:  David M Lonard; Rainer B Lanz; Bert W O'Malley
Journal:  Endocr Rev       Date:  2007-07-03       Impact factor: 19.871

Review 5.  Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation.

Authors:  David M Lonard; Bert W O'malley
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

6.  SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock.

Authors:  Ray-Chang Wu; Qin Feng; David M Lonard; Bert W O'Malley
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

Review 7.  Subnuclear trafficking and gene targeting by steroid receptors.

Authors:  Akhilesh K Nagaich; Geetha V Rayasam; Elisabeth D Martinez; Matthias Becker; Yi Qiu; Thomas A Johnson; Cem Elbi; Terace M Fletcher; Sam John; Gordon L Hager
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

8.  Estrogen induces expression of BCAS3, a novel estrogen receptor-alpha coactivator, through proline-, glutamic acid-, and leucine-rich protein-1 (PELP1).

Authors:  Anupama E Gururaj; Shaohua Peng; Ratna K Vadlamudi; Rakesh Kumar
Journal:  Mol Endocrinol       Date:  2007-05-15

9.  Sequence and characterization of a coactivator for the steroid hormone receptor superfamily.

Authors:  S A Oñate; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Science       Date:  1995-11-24       Impact factor: 47.728

Review 10.  MTA family of coregulators in nuclear receptor biology and pathology.

Authors:  Bramanandam Manavathi; Kamini Singh; Rakesh Kumar
Journal:  Nucl Recept Signal       Date:  2007-11-30
View more
  54 in total

1.  Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.

Authors:  Victoria Wargon; Marina Riggio; Sebastián Giulianelli; Gonzalo R Sequeira; Paola Rojas; María May; María L Polo; María A Gorostiaga; Britta Jacobsen; Alfredo Molinolo; Virginia Novaro; Claudia Lanari
Journal:  Int J Cancer       Date:  2014-11-12       Impact factor: 7.396

2.  ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.

Authors:  Ekaterina V Kalashnikova; Alexey S Revenko; Abigael T Gemo; Nicolas P Andrews; Clifford G Tepper; June X Zou; Robert D Cardiff; Alexander D Borowsky; Hong-Wu Chen
Journal:  Cancer Res       Date:  2010-09-23       Impact factor: 12.701

Review 3.  Mi-2/NuRD complex making inroads into DNA-damage response pathway.

Authors:  Da-Qiang Li; Rakesh Kumar
Journal:  Cell Cycle       Date:  2010-06-01       Impact factor: 4.534

4.  Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.

Authors:  Vijay K Gonugunta; Gangadhara R Sareddy; Samaya Rajeshwari Krishnan; Valerie Cortez; Sudipa Saha Roy; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Mol Cancer Ther       Date:  2014-03-31       Impact factor: 6.261

5.  Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation.

Authors:  Belen Elguero; Geraldine Gueron; Jimena Giudice; Martin A Toscani; Paola De Luca; Florencia Zalazar; Federico Coluccio-Leskow; Roberto Meiss; Nora Navone; Adriana De Siervi; Elba Vazquez
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

6.  ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.

Authors:  Feng Jin; Shazia Irshad; Wei Yu; Madesh Belakavadi; Marina Chekmareva; Michael M Ittmann; Cory Abate-Shen; Joseph D Fondell
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

7.  Modulation of testosterone-dependent male sexual behavior and the associated neuroplasticity.

Authors:  Thierry D Charlier; Aurore L Seredynski; Neville-Andrew Niessen; Jacques Balthazart
Journal:  Gen Comp Endocrinol       Date:  2013-03-20       Impact factor: 2.822

8.  In utero exposure to bisphenol A shifts the window of susceptibility for mammary carcinogenesis in the rat.

Authors:  Angela M Betancourt; Isam A Eltoum; Renee A Desmond; Jose Russo; Coral A Lamartiniere
Journal:  Environ Health Perspect       Date:  2010-11       Impact factor: 9.031

9.  PRIC295, a Nuclear Receptor Coactivator, Identified from PPARα-Interacting Cofactor Complex.

Authors:  Sean R Pyper; Navin Viswakarma; Yuzhi Jia; Yi-Jun Zhu; Joseph D Fondell; Janardan K Reddy
Journal:  PPAR Res       Date:  2010-09-05       Impact factor: 4.964

10.  Coactivators in PPAR-Regulated Gene Expression.

Authors:  Navin Viswakarma; Yuzhi Jia; Liang Bai; Aurore Vluggens; Jayme Borensztajn; Jianming Xu; Janardan K Reddy
Journal:  PPAR Res       Date:  2010-08-05       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.